Mercaptamine ophthalmic - Orphan Europe

Drug Profile

Mercaptamine ophthalmic - Orphan Europe

Alternative Names: Cystadrops; Cysteamine chlorhydrate - Orphan Europe; Cysteamine hydrochloride - Orphan Europe; Mercaptamine hydrochloride - Orphan Europe

Latest Information Update: 31 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orphan Europe
  • Class Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinosis
  • New Molecular Entity No

Highest Development Phases

  • Registered Cystinosis

Most Recent Events

  • 27 Jan 2017 Registered for Cystinosis (In adolescents, In children, In adults) in European Union, Norway, Iceland and Liechtenstein (Ophthalmic)
  • 14 Oct 2016 Committee for Medicinal Products for Human Use (CHMP) recommends approval of mercaptamine for Cystinosis in European Union
  • 31 Dec 2014 Preregistration for Cystinosis in European Union (Ophthalmic) (before December (Recordati, Annual Report,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top